bluebird bio plunges as financials and business update displease

10 August 2021
bluebird_bio_large

US biotech bluebird bio (Nasdaq: BLUE) yesterday reported financial results and business highlights for the second quarter ended June 30, 2021, which failed to impress investors, so the stock tumbled 27.5% to $18.16 by close of trading.

Total revenues were $7.5 million for the three months ended June 30, 2021 compared to $198.9 million in the like 2020 period. Net loss was $241.7 million for the 2021 three months compared to $21.5 million a year ago.

FDA clinical hold

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology